Organovo Holdings Inc (ONVO)
$1.34
Insights on Organovo Holdings Inc
Increasing Revenue
Revenue is up for the last 3 quarters, 77.0K → 162.0K (in $), with an average increase of 26.2% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -7.45M → -6.99M (in $), with an average increase of 6.6% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 91.4% return, outperforming this stock by 126.0%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 165.8% return, outperforming this stock by 244.8%
Performance
- $1.30$1.38$1.34
2.98%
Downside
Day's Volatility :5.79%
Upside
2.9%
- $1.00$3.40$1.34
25.37%
Downside
52 Weeks Volatility :70.59%
Upside
60.59%
Returns
| Period | Organovo Holdings Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -19.52% | -0.9% | 0.0% |
6 Months | -40.97% | 1.5% | 1.0% |
1 Year | -34.63% | 7.1% | 6.4% |
3 Years | -80.44% | 25.9% | 19.9% |
Highlights
Market Capitalization | 12.0M |
Book Value | $1.35 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -1.99 |
PEG Ratio | 0.0 |
Wall Street Target Price | 3.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -4199.33% |
Return On Assets TTM | -51.56% |
Return On Equity TTM | -91.67% |
Revenue TTM | 445.0K |
Revenue Per Share TTM | 0.05 |
Quarterly Revenue Growth YOY | -89.2% |
Gross Profit TTM | -8.5M |
EBITDA | -18.4M |
Diluted Eps TTM | -1.99 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 123.88%
Technicals Summary
Sell
Neutral
Buy
Organovo Holdings Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Organovo Holdings Inc | 16.52% | -40.97% | -34.63% | -80.44% | -94.22% |
 Moderna, Inc. | -13.8% | -33.86% | -19.73% | 39.08% | 427.53% |
 Regeneron Pharmaceuticals, Inc. | 0.18% | 1.46% | 19.77% | 45.55% | 105.03% |
 Novo Nordisk A/s | -2.09% | 18.67% | 91.43% | 165.4% | 285.43% |
 Seagen, Inc. | 4.8% | 8.3% | 59.7% | 13.46% | 176.24% |
 Vertex Pharmaceuticals Incorporated | 0.03% | 14.01% | 23.51% | 31.36% | 85.35% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Organovo Holdings Inc | NA | NA | 0.0 | 0.0 | -0.92 | -0.52 | 0.0 | 1.35 |
Moderna, Inc. | 35.31 | 35.31 | 0.0 | -3.66 | 0.07 | 0.01 | 0.0 | 44.49 |
Regeneron Pharmaceuticals, Inc. | 21.73 | 21.73 | 9.01 | 41.82 | 0.19 | 0.1 | 0.0 | 225.94 |
Novo Nordisk A/s | 42.99 | 42.99 | 2.03 | 1.65 | 0.82 | 0.22 | 0.01 | 2.52 |
Seagen, Inc. | NA | NA | 18.53 | -3.52 | -0.26 | -0.13 | 0.0 | 13.96 |
Vertex Pharmaceuticals Incorporated | 27.12 | 27.12 | 0.41 | 14.71 | 0.25 | 0.16 | 0.0 | 60.01 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Organovo Holdings Inc | Hold | $12.0M | -94.22% | NA | 0.0% |
Moderna, Inc. | Buy | $37.4B | 427.53% | 35.31 | 11.33% |
Regeneron Pharmaceuticals, Inc. | Buy | $90.4B | 105.03% | 21.73 | 33.93% |
Novo Nordisk A/s | Buy | $407.6B | 285.43% | 42.99 | 33.4% |
Seagen, Inc. | Hold | $40.6B | 176.24% | NA | -33.55% |
Vertex Pharmaceuticals Incorporated | Buy | $90.8B | 85.35% | 27.12 | 35.4% |
Institutional Holdings
Vanguard Group Inc
3.25%BlackRock Inc
1.69%Renaissance Technologies Corp
1.50%Geode Capital Management, LLC
0.74%Morgan Stanley - Brokerage Accounts
0.63%Susquehanna International Group, LLP
0.47%
Corporate Announcements
Organovo Holdings Inc Earnings
Organovo Holdings Inc’s price-to-earnings ratio stands at None
Read More
Company Information
organovo (nyse mkt: onvo) designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. the company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. these 3d human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. in addition to numerous scientific publications, their technology has been featured in the wall street journal, time magazine, the economist, and other outlets. organovo is changing the shape of medical research and practice.
Organization | Organovo Holdings Inc |
Employees | 23 |
CEO | Mr. Keith E. Murphy |
Industry | Health Technology |
